Pronto disponible para inscripción

This study will open for enrollment soon. Please contact the study team for more information and check back frequently.

Harmoni-7 1st Line metastatic Non-Small Cell Lung Cancer with high PDL-1 - Clinical Trial

¿Cuál es el Propósito de este estudio?

We are doing this study to find the most effective, safe dose of an experimental drug called ivonescimab (the study drug) compared to pembrolizumb in adults with metastatic non-small cell lung cancer (NSCLC).

¿Cuál es la Condición que se está estudiando?

Non-small Cell Lung Cancer (NSCLC)

¿Quién puede participar en el Estudio?

Adults ages 18+ who:

Are diagnosed with metastatic (Stage IV) NSCLC
Have high PD-L1 expression based tumor tissue testing
Have not received any previous systemic treatment targeted toward metastatic NSCLC
Have no known genomic alterations (e.g., EGFR, ALK, ROS1, and BRAF V600E) based on testing

For more information, contact the study team at annemarie.peters@duke.edu.

Grupo etario

Adultos

¿Qué Implica?

Si decide unirse a este estudio, recibirá una asignación aleatoria (como lanzar una moneda al aire) para:

Obtener el fármaco del estudio; O
Get the standard treatment, which is pembrolizumab

Regardless of your drug assignment, you will get and intravenous (IV) infusion every 3 weeks of either the study drug or pembrolizumab. The infusions will last for 1-2 hours each. You will get infusions for up to 2 years.

Detalles del Estudio

Título Completo

A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression (HARMONi-7)

Investigador Principal